Q-omics provides the consensus-scored MECR profile across patient tissues and cancer cell-line models. MECR expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, MECR is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, MECR RNA expression shows 18,019 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, COAD, and ACC as cancer lineages where MECR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MECR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MECR survival associations across molecular data types. MECR RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MECR RNA expression–survival associations across cancer types. High MECR expression shows unfavorable associations in KICH, BLCA, SKCM, LGG and PAAD, but favorable associations in KIRP. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify KICH as the clearest survival context for MECR RNA expression.
This table summarizes MECR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MECR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MECR shows lower tumor expression in BRCA and higher tumor expression in COAD, LUAD, LIHC, BLCA and LUSC. The COAD box plot shows higher MECR RNA expression in tumor versus normal tissue (log2 FC = +0.719, t-test p < 0.001).
This table shows molecular features associated with MECR in patient tissues and cancer cell lines. In patient samples, MECR shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MECR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
